MIAMI BEACH, Fla., Oct. 1, 2026 /PRNewswire/ -- Mount Sinai Medical Center is proud to announce the appointment of Olcay Aksoy, MD, a nationally recognized academic cardiologist, structural heart specialist, and physician leader, as Chief of Cardiology. Dr. Aksoy joins the medical center from UCLA Health, where he served as Director of the Structural Heart Program, Director of Aortic Valve Interventions, Associate Director of Clinical Research in Cardiology, and Associate Professor of Medicine.

BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on September 30, 2026, Edgewise granted inducement stock options to purchase a total of 7,500 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 3,751 shares of Edgewise's common stock to 3 new non-

CLEVELAND, Oct. 1, 2026 /PRNewswire/ -- Arrowfly today launched its Medical Design & Outsourcing Medtech Innovation Board, an invitation-only medical device innovation community that brings together experts from device developers, manufacturers and their supply chain partners to collaborate on the trends, technologies and challenges shaping the future of healthcare. As part of Arrowfly's new Industry Leadership Boards initiative, the MDO Medtech Innovation Board will hold quarterly meetings of

9月28日，NMPA官网显示，默沙东PD-1抑制剂帕博利珠单抗注射液（皮下注射）在国内获批上市，成为国内首个获批上市的PD-1单抗皮下注射剂（受理号：JXSS2500072-JXSS2500095）。 截图来源：NMPA官网 01 K药“换剂型”，皮下注射缩短给药时间 皮下帕博利珠单抗（MK-3475A）由帕博利珠单抗+Berahyaluronidase alfa（ALT-B4）组成。其中，ALT-B4为韩国Alteogen开发的重组人透明质酸酶变体。 来源：摩熵医药全球药物研发数据库（查数据.找摩熵） 2024年2月，默沙东与Alteogen达成合作，以2000万美元首付款+4.32亿美元里程碑付款获得ALT-B4。 透明质酸酶能够降解皮下组织中的透明质酸，降低组织黏度，促进大分子药物扩散和吸收，从而实现抗体药物的皮下注射。 与传统静脉输注相比，皮下帕博利珠单抗可采用每3周一次或每6周一次的给药方案，单次注射时间明显缩短。美国FDA批准的Keytruda Qlex同样采用每3周或每6周给药方案。 02 III期研究显示，皮下给药疗效与安全性保持一致 皮下帕博利珠单抗的关键III期研究

New name and digital experience reflect a unified vision for compassionate, personalized and advanced specialty care across Southern California LOS ANGELES, Oct. 1, 2026 /PRNewswire/ -- Los Angeles Cancer Network today officially launches as Oncura Health, marking the network-wide transition to a new name and identity designed to better reflect the organization's growing reach, clinical capabilities and commitment to community-based specialty care. Continue Reading Same Great Team. New Name. Th

The $100M+ social-first brand continues their investment in breast cancer research focused on younger women with the Breast Cancer Research Foundation as rates of incidence in women under 40 rise, donating 30% of October Give Back Bundle revenue with an annual commitment of $250K. LOS ANGELES, Oct. 1, 2026 /PRNewswire/ -- CAKES body, the category-defining brand creating innovative boob solutions and invisible essentials, today announced the next phase of its commitment to women's health with the

BRANFORD, Conn., Oct. 1, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the completion of Cohort 1 in its Phase 1/2 clinical trial evaluating ATR04-484 as a potential treatment for EGFR inhibitor (EGFRi)-associated skin rash. Following its review of available safety data from patients enrolled in Cohort 1, the study's safety review

MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings High MUC16 Expression Was Associated with Poor Real-World Overall Survival in High-Grade Serous Ovarian Carcinoma, the Most Common Subtype of Ovarian Cancer Findings Reinforce the Scientific Rationale for HWK-016, Whitehawk's Next-Generation MUC16-Directed ADC Currently in Phase 1 Development MORRISTOWN, N.J., Oct. 1, 2026 /PRNewswi

糖尿病足溃疡有多难缠？不少患者脚上只是磨破一点皮，最后却发展到反复感染、伤口经久不愈，甚至面临截肢风险。 中国糖尿病患病率持续攀升，糖尿病足溃疡的终身发生风险约为15%至25%，一旦合并感染，截肢率和死亡率显著升高。问题在于，这类伤口常陷入恶性循环：细菌在创面形成生物膜，抗生素难以渗透；持续感染又引发氧化应激和慢性炎症，损伤血管内皮，进一步削弱组织供血和修复能力。传统抗生素和被动敷料各管一头，很难同时打破这个循环。 近日，Journal of Nanobiotechnology发表一项研究，用一种超声响应的抗菌肽复合水凝胶FFRK8@ZnO@fHAMA，尝试把杀菌和组织修复放到同一个体系里完成。 这个水凝胶由三部分组成：人宿主防御肽来源的FFRK8、微环境响应ZnO2微球，以及鱼胶原修饰的透明质酸甲基丙烯酸酯。低强度脉冲超声照射下，FFRK8被激活，ZnO2在感染酸性环境中释放过氧化氢和氧，水凝胶则负责把有效成分留在伤口局部。表征显示，ZnO2呈均匀球形，肽负载后结构完整；水凝胶保持多孔网络，FFRK8和Zn2+随时间缓释，酸性条件促进释放。 体外抗菌实验中，超声激活复合水凝胶对耐甲氧

当你读完这行文字的短暂瞬间，世界上就会有一名 50 岁以上女性遭遇骨质疏松相关的脆性骨折。骨质疏松被称作 “沉默的骨骼杀手”，它悄无声息地破坏骨骼结构完整性，损害人体行动能力，疾病以骨量下降、骨矿物质密度降低为特征，让骨骼质地变脆、极易发生断裂，在欧美及日本地区合计约有 7500 万人深受其扰。绝经后雌激素水平的跌落进一步加重女性患病负担，全球 50 岁以上女性中，每 3 人就有 1 人面临骨质疏松脆性骨折的威胁，骨折带来的疼痛、活动受限，还会同步拖累患者心理状态与社会生活质量。 发表于 Cell 的一项首次人体 Ⅰ 期临床试验，带来了晚期骨质疏松细胞治疗的突破性进展，这项技术巧妙修饰患者自身干细胞的细胞表面糖萼，赋予干细胞 “生物导航标签”，帮助静脉输注的细胞精准结合骨髓微血管，定向奔赴受损的骨骼组织发挥修复作用。 该研究一共纳入 10 名 50‑75 岁罹患晚期骨质疏松的女性受试者，全部受试者接受单次静脉输注经过岩藻糖外修饰处理的自体骨髓来源间充质干细胞（Fuc‑autoBM‑MSCs）。在方案规定的两年核心观察周期内，受试者脆性骨折的发生事件大幅下降 94%，骨折发生规模从每年